Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.
Miyata R, Hamaji M, Kawaguchi A, Shimazu Y, Ikeda M, Ishikawa M, Kayawake H, Menju T, Kobayashi M, Okumura N, Sakaguchi Y, Sonobe M, Matsumoto A, Shoji T, Katakura H, Sumitomo R, Huang CL, Takahashi M, Aoyama A, Muranishi Y, Kono T, Miyahara R, Date N, Fujinaga T, Miyamoto E, Nakagawa T, Fukada T, Sakai H, Date H.
Miyata R, et al. Among authors: miyahara r.
Eur J Cardiothorac Surg. 2022 Oct 4;62(5):ezac430. doi: 10.1093/ejcts/ezac430.
Eur J Cardiothorac Surg. 2022.
PMID: 35997576